As the pace of technological advances accelerates, the ILP is committed to translating fundamental discoveries into productive, applied interaction with industry.
The agreement aims to develop a mutually beneficial relationship between
Lonza is committed to delivering increasingly complex medicines to market in record time and to anticipate the requirements for scaling emerging modalities, ensuring innovation in medicines reaches patients.
About Lonza
Lonza is a leading global supplier to the pharmaceutical, biotech and specialty ingredients markets. We work to promote a healthier lifestyle and prevent illness by supporting our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. This is complemented by our broad range of microbial control solutions, which help to create and maintain a healthy environment.
Patients and consumers benefit from how we apply our scientific knowledge and advanced manufacturing technologies to the healthcare, hygiene and fast-moving consumer goods markets and to developing preservation and protection materials.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide (at the end of 2019). The company generated sales of
Contact:
Dr.
Tel: +41 61 316 8782
Email: kristin.koehler@lonza.com
Additional Information and Disclaimer
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of
(C) 2020 Electronic News Publishing, source